GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (STU:S0Z0) » Definitions » Total Liabilities

Sientra (STU:S0Z0) Total Liabilities : €161.14 Mil (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Sientra Total Liabilities?

Sientra's Total Liabilities for the quarter that ended in Sep. 2023 was €161.14 Mil.

Sientra's quarterly Total Liabilities declined from Mar. 2023 (€152.73 Mil) to Jun. 2023 (€151.95 Mil) but then increased from Jun. 2023 (€151.95 Mil) to Sep. 2023 (€161.14 Mil).

Sientra's annual Total Liabilities increased from Dec. 2020 (€139.36 Mil) to Dec. 2021 (€140.76 Mil) and increased from Dec. 2021 (€140.76 Mil) to Dec. 2022 (€156.54 Mil).


Sientra Total Liabilities Historical Data

The historical data trend for Sientra's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra Total Liabilities Chart

Sientra Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.20 110.27 139.36 140.76 156.54

Sientra Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.97 156.54 152.73 151.95 161.14

Sientra Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sientra's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=85.291+(57.512+11.106
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+2.635+0)
=156.54

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=156.157--0.386
=156.54

Sientra's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=142.51+(3.869+13.083
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.681+0)
=161.14

Total Liabilities=Total Assets (Q: Sep. 2023 )-Total Equity (Q: Sep. 2023 )
=131.117--30.026
=161.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sientra Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sientra's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Sientra (STU:S0Z0) Business Description

Traded in Other Exchanges
Address
3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612
Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.

Sientra (STU:S0Z0) Headlines

No Headlines